Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Wed, 08/26/15 - 09:28 am
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off
Motley Fool
Sat, 08/22/15 - 09:01 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
BioMarin outlines its R&D game plan as Duchenne MD decision nears
Fierce Biotech
Tue, 08/4/15 - 05:51 pm
Biomarin
R&D
Duchenne Muscular Dystrophy
drisapersen
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs
TheStreet.com
Mon, 07/20/15 - 02:37 pm
FDA
Biomarin
advisory panels
eteplirsen
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
Sarepta Therapeutics One Step Closer to Drug Approval
Investopedia
Fri, 07/3/15 - 08:00 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Sarepta Submits DMD Drug for FDA Approval Review
TheStreet.com
Mon, 06/29/15 - 10:48 am
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
FDA finally responds to demand for Duchenne Muscular Dystrophy guidance
BioPharma Dive
Wed, 06/10/15 - 10:58 am
FDA
Duchenne Muscular Dystrophy
Saretpa
PTC Therapeutics
Pfizer
Biomarin
FDA Tells Sarepta Therapeutics: Come on Down With Your DMD Drug!
TheStreet.com
Tue, 05/19/15 - 05:02 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
eteplirsen
Why BioMarin’s New Drug Application is Good News for Sarepta Therapuetics
Fierce Pharma Marketing
Wed, 05/6/15 - 11:44 am
Biomarin
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
Bloomberg
Wed, 04/15/15 - 09:01 am
Santhera
Duchenne Muscular Dystrophy
Catena
Summit pulls off a downsized IPO for its DMD drug
Fierce Biotech
Thu, 03/5/15 - 08:55 am
Duchenne Muscular Dystrophy
Summit Therapeutics
SMT C1100
IPOs
8 Biotech Stock Controversies Emerging From 'JPM15' Conference
TheStreet.com
Tue, 01/20/15 - 11:33 am
JPMHC 2015
drug pricing
CAR-T
biotech
Gilead Sciences
immuno-oncology
Duchenne Muscular Dystrophy
BioMarin CEO Angers Sarepta CEO With Slides Comparing Trial Data
WSJ Pharmalot
Sat, 01/17/15 - 11:01 am
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biotech Rivalry Gets Nasty in Mudslinging Battle Over Data
Bloomberg
Thu, 01/15/15 - 09:28 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
BioMarin CEO Sees Big Future For Prosensa Drug
Investors.com
Wed, 12/24/14 - 08:58 am
Biomarin
Prosensa
drisapersen
Duchenne Muscular Dystrophy
Pfizer bets on Duchenne MD treatment
Medical Marketing and Media
Thu, 12/18/14 - 04:30 pm
Pfizer
Duchenne Muscular Dystrophy
Translarna
A ‘Strange Back and Forth’ Between Sarepta and the FDA
WSJ Pharmalot
Fri, 10/31/14 - 02:13 pm
Sarepta Therapeutics
FDA
eteplirsen
Duchenne Muscular Dystrophy
Sarepta timeline delayed on muscular dystrophy drug
CNBC
Mon, 10/27/14 - 08:51 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study
The Chairman's Blog
Mon, 10/13/14 - 04:09 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Pages
« first
‹ previous
…
11
12
13
14
15
16
17
18
19
next ›
last »